A political 'bomb' over drug prices could threaten NAFTA 2.0
The pact would also give pharmaceutical companies 10 years' protection from cheaper competition in a category of ultra-expensive drugs called biologics.
The pact would also give pharmaceutical companies 10 years' protection from cheaper competition in a category of ultra-expensive drugs called biologics.